Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of MS201408-0005A as Single Agent and Sequentially in Combinations With MS201408-0005C or MS201408-0005B in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors

Trial Profile

Phase I, First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of MS201408-0005A as Single Agent and Sequentially in Combinations With MS201408-0005C or MS201408-0005B in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2018

At a glance

  • Drugs MS-201408-0005-A-EMD-Serono (Primary) ; MS-201408-0005B-EMD-Serono (Primary) ; MS-201408-0005C-EMD-Serono (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors EMD Serono Research & Development Institute
  • Most Recent Events

    • 13 Nov 2018 Planned End Date changed from 3 Sep 2020 to 1 Feb 2019.
    • 13 Nov 2018 Planned primary completion date changed from 7 Apr 2019 to 1 Feb 2019.
    • 13 Nov 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top